LivaNova (NASDAQ:LIVN) Raised to Hold at Freedom Capital

Posted by Brian Himes on Jul 3rd, 2026

LivaNova (NASDAQ:LIVN – Get Free Report) was upgraded by Freedom Capital to a “hold” rating in a note issued to investors on Tuesday,Zacks.com reports.

A number of other research firms have also recently weighed in on LIVN. Barclays boosted their target price on shares of LivaNova from $73.00 to $76.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 7th. Robert W. Baird dropped their target price on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Weiss Ratings raised shares of LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research report on Thursday, May 7th. Mizuho increased their target price on shares of LivaNova from $85.00 to $90.00 and gave the company an “outperform” rating in a report on Thursday, May 7th. Finally, KeyCorp upped their price objective on LivaNova from $83.00 to $92.00 and gave the company an “overweight” rating in a research note on Monday, June 22nd. Six research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, LivaNova has a consensus rating of “Moderate Buy” and a consensus target price of $80.75.

View Our Latest Report on LIVN

LivaNova Trading Up 1.4%

Shares of LivaNova stock opened at $83.62 on Tuesday. LivaNova has a 1 year low of $41.01 and a 1 year high of $83.98. The company has a market capitalization of $4.59 billion, a price-to-earnings ratio of 42.88 and a beta of 0.86. The business has a fifty day simple moving average of $73.58 and a two-hundred day simple moving average of $67.51. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.33 and a quick ratio of 1.11.

LivaNova (NASDAQ:LIVN – Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.13. The business had revenue of $362.26 million during the quarter, compared to analysts’ expectations of $346.05 million. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The firm’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same period last year, the firm posted $0.88 EPS. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. Research analysts forecast that LivaNova will post 3.73 EPS for the current year.

Insider Activity at LivaNova

In related news, Director Francesco Bianchi sold 1,800 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $75.75, for a total value of $136,350.00. Following the transaction, the director directly owned 7,228 shares in the company, valued at approximately $547,521. This represents a 19.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.35% of the company’s stock.

Hedge Funds Weigh In On LivaNova

Several institutional investors have recently modified their holdings of the company. Hantz Financial Services Inc. grew its position in LivaNova by 159.9% during the fourth quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock valued at $27,000 after acquiring an additional 267 shares during the last quarter. State of Wyoming bought a new position in shares of LivaNova during the second quarter valued at about $31,000. EverSource Wealth Advisors LLC grew its position in shares of LivaNova by 998.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock worth $32,000 after buying an additional 639 shares during the last quarter. Quarry LP bought a new position in LivaNova in the third quarter worth about $36,000. Finally, Covestor Ltd lifted its holdings in LivaNova by 108.6% in the fourth quarter. Covestor Ltd now owns 753 shares of the company’s stock worth $46,000 after buying an additional 392 shares during the period. 97.64% of the stock is currently owned by institutional investors.

LivaNova Company Profile

(Get Free Report)

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.